(provided by the applicant): The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) Is the renamed renewal of "Chiang Mai University HIV/AIDS Clinical Trials Unit- Sirisanthana, Thira" (Grant# U01 Al 069399, Feb 2007-Jan 2014), which expands beyond the Chiang Mai University Research Institute for Health Sciences (CMU-RIHES) to add the experience and resources of another major HIV research institution: the Thai Red Cross AIDS Research Centre (TRC-ARC), affiliated with Chulalongkorn University.
The aim of the THAI CTU Is to collaborate with five Clinical Research Networks established by NIAID, NIH under RFA-AI-12-001, -004, -008, -011, and -012, in coordinating and executing clinical research in Thailand and the neighboring region to expand knowledge and improve treatment and prevention of HIV and related Infectious diseases. It also aims to assist the CRNs In refining their research agendas to meet the needs, priorities, circumstances, and sensitivities of low- and middle-income countries in hosting research studies, so that findings are of utility fo preventing and treating HIV and related conditions both universally, as well as in the country of research. Located in the cities of Chiang Mai and Bangkok, Thailand, the THAI CTU is led by Co-Principal Investigators Suwat Chariyalertsak and Kiat Ruxrungtham, plus P. Phanuphak, T. Sirisanthana, K. Supparatpinyo, G.J.P.(F) van Griensven, V. Sirisanthan, A. Avihingsanon, T. Puthanakit, and K. Srithanaviboonchal. It is comprised of four Clinical Research Sites which will implement clinical and related HIV studies on maternal, pediatric, and adult therapeutics, on topical microbicides to prevent HIV transmission, on Integrated population-based prevention strategies, and on vaccines. After appropriate community and ethical approvals, such studies will be conducted on volunteers from populations with both high and usual risk for HIV, including those seeking voluntary counseling and testing or healthcare, men who have sex with men and transgender women, HIV-discordant couples, persons who inject drugs, pregnant, neonates, children, adolescents, blood donors, and persons from the general population.

Public Health Relevance

Enlightened prevention programs reduced HIV transmission in Thailand, a beachhead for the explosive arrival of HIV into Asia in the 1980s. However, new infections remain unacceptably frequent. Thai Institutions as RIHES and TRC-ARC provide infrastructure, population access, and indigenous scientific expertise and leadership for valuable clinical research of global, regional, and local application in controlling the epidemic.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-BP-A (S3))
Program Officer
Castillo, Blanca E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Chiang Mai University
Chiang Mai
Zip Code
Wallis, Carole L; Aga, Evgenia; Ribaudo, Heather et al. (2014) Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis 59:706-15
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Mollan, Katie R; Smurzynski, Marlene; Eron, Joseph J et al. (2014) Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 161:1-10
Watts, D Heather; Stek, Alice; Best, Brookie M et al. (2014) Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr 67:375-81
Havers, Fiona P; Detrick, Barbara; Cardoso, Sandra W et al. (2014) Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings. PLoS One 9:e95164
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60